We use cookies to ensure that we give you the best experience on our website. By continuing to browse the site you are agreeing to our use of cookies. If you would like to know more please click here.


What we do

Cyclofluidic is using CyclOps™, its proprietary microfluidic drug discovery platform, to revolutionise hit and lead optimisation.

CyclOps™ connects flow chemistry, purification, screening and drug design with complex algorithms allowing drug lead molecules to be assayed minutes, rather than weeks, after they are designed. Using the power of flow chemistry, developed in the labs of Prof Steve Ley at Cambridge University, our unique approach puts synthesis, screening and molecular design firmly back together in a single laboratory allowing fast iterative exploration of vast areas of diverse chemical space.

CyclOps™ is the ultimate lean approach to lead discovery, allowing us to optimise hits in real time, making and screening only those key compounds that progress a hypothesis towards the best possible lead molecules.



Case Study

Read how Cyclofluidic used the CyclOps™ platform with our partners to discover novel and potent Abl1 inhibitors with broad mutant activity

Who we work with

feature 1


Leveraging our decades of big pharma experience to solve medicinal chemistry problems

feature 1

BioTech Companies

Using our strength and depth in pharmaceutical chemistry to generate chemical matter IP in innovative risk sharing partnerships

feature 1

Not for Profit

Exploiting the built in drug discovery knowledge in the CyclOps™ platform to help solve global health challenges